8-K: TuHURA Biosciences Announces Investor Presentation Highlighting Clinical Milestones and Acquisition of Kineta's VISTA Inhibitor

TuHURA Biosciences updates investors on its clinical programs, including the planned Phase 3 trial for IFx-2.0 and the acquisition of Kineta's VISTA inhibiting mAb, with key data readouts expected over the next 24 months.

Summary

• TuHURA Biosciences has begun investor presentations on March 18, 2025, focusing on overcoming resistance to cancer immunotherapy.
• The company is advancing its IFx-Hu2.0 product candidate and IFx-Hu3.0 preclinical program, along with tumor microenvironment modulators.
• A key highlight is the planned acquisition of Kineta, Inc., including Kineta's VISTA-101 development program.
• TuHURA anticipates initiating a Phase 3 registration study for IFx-2.0 in 1st line Merkel Cell Cancer in 1H 2025, pending resolution of a partial clinical hold related to CMC requirements.
• A Phase 2a/b study for IFx-Hu2.0 in primary checkpoint inhibitor resistant metastatic cancer is also expected to begin in 1H 2025.
• The company expects to initiate IND-enabling studies for IFx-3.0 in Diffuse Large B-Cell Lymphoma (DLBCL) in 2H 2026.
• TuHURA plans to initiate a Phase 2a/b trial for the VISTA inhibiting mAb in NPM1 mutated Acute Myeloid Leukemia (AML) in 2H 2025, contingent on completing the Kineta merger.
• Top-line data from the Phase 3 trial is anticipated in 2H 2026.
• The company raised $31 million to fund operations through 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with upcoming clinical milestones and the acquisition of a promising asset, but the partial clinical hold and uncertainties around the Kineta merger temper the enthusiasm.

Positives

• The planned Phase 3 trial for IFx-2.0 has a SPA agreement with the FDA, potentially leading to full approval without a post-marketing trial.
• The acquisition of Kineta's VISTA inhibiting mAb adds a Phase 2 ready asset to the pipeline.
• Phase 1b results for IFx-2.0 showed encouraging efficacy with durable responses in Merkel Cell Carcinoma patients resistant to checkpoint inhibitors.
• The company has a diversified immuno-oncology pipeline with multiple programs in different stages of development.
• TuHURA has a NASDAQ listing and has raised $31 million to fund operations through 2025.

Negatives

• The Phase 3 trial for IFx-2.0 is currently subject to a partial clinical hold related to CMC requirements.
• The initiation of the Phase 2a/b trial for the VISTA inhibiting mAb is contingent on the completion of the Kineta merger.
• The company acknowledges uncertainties related to Kineta's cash level and ability to continue as a going concern.

Risks

• The completion of the mergers on anticipated terms and timing is uncertain.
• There are risks related to Kineta's cash level and ability to continue as a going concern.
• Uncertainties exist regarding access to available financing, including the Concurrent Investment, to complete the Mergers.
• The price of TuHURA Common Stock and Kineta Common Stock could change before the completion of the Mergers.
• The company faces risks related to the amount of Kinetas Estimated Net Working Capital Amount at the Closing.
• The company is exposed to macroeconomic conditions and geopolitical uncertainty in the global economy.
• The biopharmaceutical sector is highly competitive.

Future Outlook

TuHURA anticipates several clinical milestones over the next 24 months, including the initiation of Phase 3 trials, Phase 2 trials, and IND-enabling studies, with top-line data from the Phase 3 trial expected in 2H 2026.

Industry Context

TuHURA is operating in the competitive biopharmaceutical sector, focusing on immuno-oncology and addressing the challenge of resistance to checkpoint inhibitors, a common issue across various tumor types.

Comparison to Industry Standards

• The document mentions Keytruda as a standard of care for 1st line therapy for advanced or metastatic Merkel cell carcinoma.
• The document references DelveInsight Merkel Cell Carcinoma (MCC) -Market Insight, Epidemiology, and Market Forecast 2034, which is a standard industry report for market analysis.
• The document references response rates to CPIs in various cancers, such as Head and Neck Cancer (15%), Lung Cancer (20%), Gastric Cancer (11%), Sarcoma (8%), Renal Cancer (23%), Colorectal Cancer (23%), Ovarian Cancer (9%), Urothelial Cancer (20%), Liver Cancer (19%), Breast Cancer (12%), Melanoma (30%), Glioblastoma (11%).

Stakeholder Impact

• Shareholders: Potential for increased value through successful clinical trials and product development.
• Patients: Access to new therapies for cancers resistant to existing treatments.
• Employees: Opportunity to work on innovative immuno-oncology programs.
• Partners: Collaboration with Merck on the VISTA inhibiting mAb program.

Next Steps

• Initiate Phase 3 trial for IFx-2.0 in 1H 2025.
• Initiate basket trial in 1H 2025.
• Complete acquisition of Kineta and initiate Phase 2 trials for VISTA inhibiting mAb in 2H 2025.
• Initiate IND-enabling studies for IFx-3.0 in 2H 2026.
• Obtain Phase 3 topline results in 2H 2026 and potentially file a BLA.

Key Dates